在心力衰竭中,-葡萄糖共载体2 (SGLT2) 抑制剂和脂质调节:叙述性综述
Sina Neshat1, Hazhir Moradi2, Matin Bidares3
1Department of Biostatistics and Epidemiology, University of California San Francisco, San Francisco, USA.
Cureus
|January 22, 2026
概括
-葡萄糖共运输体2抑制剂 (SGLT2i) 在心力衰竭 (HF) 中显示了适度的脂质变化,可能改善脂蛋白质量和代谢灵活性,有助于改善HF结果.
科学领域:
- 心脏病学 心脏病学
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉性失脂症和脂质毒性是心力衰竭 (HF) 中不良心脏重塑的关键驱动因素.
- -葡萄糖共运输体2抑制剂 (SGLT2i) 已在HF结局中显示出显著的益处,但它们对脂质资料的确切影响尚未完全理解.
研究的目的:
- 审查和合成与SGLT2i在HF患者中的使用相关的脂质参数的定量和质量变化.
- 探索SGLT2i在HF的背景下影响脂蛋白代谢的潜在机制.
主要方法:
- 临床试验的系统综述和对SGLT2i治疗患者的脂质样本进行检查的HF特异性队列.
- 分析关于定性脂蛋白重塑的新兴数据,包括LDL粒子大小和HDL子类.
- 探索涉及脂肪组织脂解,肝脏代谢和体利用的拟议机制途径.
主要成果:
- SGLT2i与LDL胆固醇 (LDL-C) 和HDL胆固醇 (HDL-C) 的轻微增加以及甘油三酸的轻微减少有关.
- 新出现的证据表明,SGLT2i可能会促进转向不那么有机的LDL表型 (例如,减少小密度LDL) 和增加HDL2水平.
- 建议的机制包括增强脂解,增加肝脏β-氧化和生成,可能为心肌提供"节省性基质".
结论:
- SGLT2i诱导了适度的定量脂质变化,但可能会在HF中产生显著的定性脂蛋白重塑,有助于改善代谢灵活性和HF结果.
- 这些脂质效应似乎独立于糖尿病状况,并表明除了传统的脂质降低之外的好处.
- 需要进一步的高风特异性试验来最终评估ApoB,sd-LDL,LDL-P,HDL功能和脂质组学,以充分阐明SGLT2i在高风脂质管理中的作用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
970
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
970
01:29Heart Failure II: Pathophysiology
790
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
790
01:17Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
01:27Heart Failure I: Introduction
729
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
729
01:22Heart Failure VI: Adjunct Therapies
278
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
278
01:22Heart Failure Drugs: Diuretics
825
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
825